Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Neal Rosen

Showing results (81-90 of 207) with videos related to

Pageof 21
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 4, 2008
SNX2112, a synthetic heat shock protein 90 inhibitor, has potent antitumor activity against HER kinase-dependent cancersSarat Chandarlapaty, Ayana Sawai, Qing Ye, et al.
Cancer Cell|September 8, 2015
BRAF Mutants Evade ERK-Dependent Feedback by Different Mechanisms that Determine Their Sensitivity to Pharmacologic InhibitionZhan Yao, Neilawattie M Torres, Anthony Tao, et al.
Cancer Discovery|February 1, 2013
Relief of feedback inhibition of HER3 transcription by RAF and MEK inhibitors attenuates their antitumor effects in BRAF-mutant thyroid carcinomasCristina Montero-Conde, Sergio Ruiz-Llorente, Jose M Dominguez, et al.
Nature|August 8, 2017
A Braf kinase-inactive mutant induces lung adenocarcinomaPatricia Nieto, Chiara Ambrogio, Laura Esteban-Burgos, et al.
Molecular Cancer Therapeutics|November 1, 2008
HER kinase activation confers resistance to MET tyrosine kinase inhibition in MET oncogene-addicted gastric cancer cellsThomas Bachleitner-Hofmann, Mark Y Sun, Chin-Tung Chen, et al.
Nature|March 26, 2015
Therapy-induced tumour secretomes promote resistance and tumour progressionAnna C Obenauf, Yilong Zou, Andrew L Ji, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 2, 2009
Phosphorylated 4E-BP1 is associated with poor survival in melanomaKathryn E O'Reilly, Melanie Warycha, Michael A Davies, et al.
Cancer Research|February 3, 2006
mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates AktKathryn E O'Reilly, Fredi Rojo, Qing-Bai She, et al.
The Journal of Investigative Dermatology|February 2, 2017
Phenformin Enhances the Efficacy of ERK Inhibition in NF1-Mutant MelanomaSebastian Trousil, Shuang Chen, Chan Mu, et al.
Scientific Reports|July 28, 2019
Global view of the RAF-MEK-ERK module and its immediate downstream effectorsCristina C Santini, James Longden, Erwin M Schoof, et al.
Pageof 21

Showing results (81-90 of 207) with videos related to

Sort By:
Pageof 21
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 4, 2008
SNX2112, a synthetic heat shock protein 90 inhibitor, has potent antitumor activity against HER kinase-dependent cancersSarat Chandarlapaty, Ayana Sawai, Qing Ye, et al.
Cancer Cell|September 8, 2015
BRAF Mutants Evade ERK-Dependent Feedback by Different Mechanisms that Determine Their Sensitivity to Pharmacologic InhibitionZhan Yao, Neilawattie M Torres, Anthony Tao, et al.
Cancer Discovery|February 1, 2013
Relief of feedback inhibition of HER3 transcription by RAF and MEK inhibitors attenuates their antitumor effects in BRAF-mutant thyroid carcinomasCristina Montero-Conde, Sergio Ruiz-Llorente, Jose M Dominguez, et al.
Nature|August 8, 2017
A Braf kinase-inactive mutant induces lung adenocarcinomaPatricia Nieto, Chiara Ambrogio, Laura Esteban-Burgos, et al.
Molecular Cancer Therapeutics|November 1, 2008
HER kinase activation confers resistance to MET tyrosine kinase inhibition in MET oncogene-addicted gastric cancer cellsThomas Bachleitner-Hofmann, Mark Y Sun, Chin-Tung Chen, et al.
Nature|March 26, 2015
Therapy-induced tumour secretomes promote resistance and tumour progressionAnna C Obenauf, Yilong Zou, Andrew L Ji, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 2, 2009
Phosphorylated 4E-BP1 is associated with poor survival in melanomaKathryn E O'Reilly, Melanie Warycha, Michael A Davies, et al.
Cancer Research|February 3, 2006
mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates AktKathryn E O'Reilly, Fredi Rojo, Qing-Bai She, et al.
The Journal of Investigative Dermatology|February 2, 2017
Phenformin Enhances the Efficacy of ERK Inhibition in NF1-Mutant MelanomaSebastian Trousil, Shuang Chen, Chan Mu, et al.
Scientific Reports|July 28, 2019
Global view of the RAF-MEK-ERK module and its immediate downstream effectorsCristina C Santini, James Longden, Erwin M Schoof, et al.
Pageof 21